Athenex, Inc.
Athenex, Inc. logo
ATNX

Athenex, Inc. (ATNX)

$0.22115.65%

Market is closed
– opens on 8 PM, 06 Feb 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$0.20121
Day's Range
$0.2795
$0.1184
52-Week Range
$1.2
1 month return17.49%
3 month return10.61%
1 year return76.87%
5 year return98.37%

Insights on Athenex, Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 24.93M → 33.53M (in $), with an average increase of 9.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -32.15M → -19.66M (in $), with an average increase of 63.5% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences, Inc. has given 35.6% return, outperforming this stock by 111.8%

  • Vs ZTS

    In the last 3 years, Zoetis Inc - Class A has given 7.4% return, outperforming this stock by 105.9%

Analyst Recommendation

based on 9 analysts ratings

Buy
77%
Buy
22%
Hold
0%
Sell

Based on 9 Wall street analysts offering stock ratings for Athenex, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 881.9%

Current

$0.22

Target

$2.17

Recommendation Trend

Based on 9 analyst

Current1M Ago3M Ago
Buy
7
7
7
Hold
2
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization30.2M
Book Value$0.16
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-1.78
PEG Ratio0.0
Wall Street Target Price2.17

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)1.08
Enterprise Value33.2M
Enterprise Value/Revenue0.27
Enterprise Value/Ebitda-0.21

Technicals

Beta1.22
50 Day MA0.18
200 Day MA0.38

Institutional Holdings

Perceptive Advisors LLC

9.87%

Vanguard Group Inc

3.41%

Millennium Management LLC

2.65%

CVI Holdings LLC

1.67%

BlackRock Inc

1.49%

Alyeska Investment Group, L.P.

1.27%

Company Information

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company's current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex's employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina.
OrganizationAthenex, Inc.
Employees652
CEODr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Athenex, Inc. share price today?

Can Indians buy Athenex, Inc. shares?

How can I buy Athenex, Inc. shares from India?

Can Fractional shares of Athenex, Inc. be purchased?

What are the documents required to start investing in Athenex, Inc. stocks?

What are today’s High and Low prices of Athenex, Inc.?

What are today’s traded volumes of Athenex, Inc.?

What is today’s market capitalisation of Athenex, Inc.?

What is the 52 Week High and Low Range of Athenex, Inc.?

How much percentage Athenex, Inc. is down from its 52 Week High?

How much percentage Athenex, Inc. is up from its 52 Week low?

What are the historical returns of Athenex, Inc.?

Who is the Chief Executive Officer (CEO) of Athenex, Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*